UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Recruiting

Conditions: Prostate Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-07-15

Last Posted Date: 2024-10-07

Lead Sponsor: University of Washington

Target Recruit Count: 450

Registration Number: NCT04472338

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Northwestern, Chicago, Illinois, United States

and more 5 locations

Transcutaneous Stimulation for Neurological Populations

Not Applicable

Recruiting

Conditions: Neurological Disorder
Cerebral Palsy

Interventions: Other: Gait Training
Device: Transcutaneous Spinal Stimulation

First Posted Date: 2020-07-13

Last Posted Date: 2023-12-11

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT04467437

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Nursing Interventions Following Sudden Cardiac Arrest

Not Applicable

Completed

Conditions: ICD

Interventions: Behavioral: Nursing intervention program

First Posted Date: 2020-07-08

Last Posted Date: 2020-07-08

Lead Sponsor: University of Washington

Target Recruit Count: 168

Registration Number: NCT04462887

Genetic and Dietary Predictors of Anti-platelet Response

Phase 4

Terminated

Conditions: Platelet Function

Interventions: Drug: Aspirin

First Posted Date: 2020-07-02

Last Posted Date: 2023-12-15

Lead Sponsor: University of Washington

Target Recruit Count: 126

Registration Number: NCT04456608

Locations: 🇺🇸
University of Montana, Missoula, Montana, United States
🇺🇸
Oregon Health & Sciences University, Portland, Oregon, United States
🇺🇸
Southcentral Foundation, Anchorage, Alaska, United States

A Hybrid Type 2 Trial of Trauma-Focused Cognitive Behavioral Therapy and a Pragmatic Individual-Level Implementation Strategy

Not Applicable

Active, not recruiting

Conditions: Evidence-Based Practices
School Health Services
Trauma, Psychological
CBT

Interventions: Behavioral: Treatment as Usual
Behavioral: Beliefs and Attitudes for Successful Implementation in Schools (BASIS)
Behavioral: Trauma-Focused Cognitive-Behavioral Therapy
Behavioral: Attention Control

First Posted Date: 2020-06-30

Last Posted Date: 2024-12-04

Lead Sponsor: University of Washington

Target Recruit Count: 34

Registration Number: NCT04451161

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Phase 2

Withdrawn

Conditions: Immune-Mediated Necrotizing Myopathy

Interventions: Drug: Gamunex-C
Drug: Albumin

First Posted Date: 2020-06-29

Last Posted Date: 2022-10-24

Lead Sponsor: University of Washington

Registration Number: NCT04450654

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Vitamin K Supplementation Study in Healthy Volunteers (Aim 2B)

Not Applicable

Terminated

Conditions: Vitamin K Status

Interventions: Genetic: Phase I, Buccal Swab Collection for DNA Isolation
Dietary Supplement: Phase II, Vitamin K (Vitacost) Supplementation

First Posted Date: 2020-06-29

Last Posted Date: 2023-12-19

Lead Sponsor: University of Washington

Target Recruit Count: 106

Registration Number: NCT04450212

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Naproxen Pharmacogenetic Study (Project 1, Aim 2)

Phase 4

Conditions: Pharmacogenetics

Interventions: Drug: Naproxen tablet

First Posted Date: 2020-06-26

Last Posted Date: 2020-06-29

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT04449471

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Phase 2

Terminated

Conditions: BCLC Stage C Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma

Interventions: Drug: Cabozantinib S-malate
Biological: Pembrolizumab

First Posted Date: 2020-06-22

Last Posted Date: 2023-04-05

Lead Sponsor: University of Washington

Target Recruit Count: 2

Registration Number: NCT04442581

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core

Not yet recruiting

Conditions: Alzheimer Disease

Interventions: Drug: investigational radiotracer [18F]MK6240

First Posted Date: 2020-06-18

Last Posted Date: 2022-11-02

Lead Sponsor: University of Washington

Target Recruit Count: 300

Registration Number: NCT04437290

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy